This website or its third-party tools process personal data. You can opt out of the sale of your personal information by clicking on the “Do Not Sell or Share My Personal Information” link.
Powered by
Opt-out Preferences
We use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. However, you can opt out of these cookies by checking "Do Not Sell or Share My Personal Information" and clicking the "Save My Preferences" button. Once you opt out, you can opt in again at any time by unchecking "Do Not Sell or Share My Personal Information" and clicking the "Save My Preferences" button.
Celebrex, manufactured by Upjohn US 2 LLC, is a nonsteroidal anti-inflammatory drug (NSAID) prescribed for treating rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis, providing pain relief and reducing inflammation while offering a lower risk of gastrointestinal issues compared to traditional NSAIDs.
Celebrex is an oral NSAID capsule with moderate side effects, interaction risks, and special population cautions. It requires regular monitoring for cardiovascular and renal health, has low misuse potential, simple dosing, and generally good adherence, aligning with FDA ACNU safety and usability considerations.
ACNU Feasibility Scorecard
Chart with 11 data points.
Celebrex
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying ← Lower is Better!. Data ranges from 1 to 6.
Safety & Risk ProfileSeverity of Side EffectsOverdose PotentialRisk of MisuseDrug-Drug InteractionsSpecial ConsiderationsUsability DifficultyDosing ComplexityMonitoring RequirementsAdherence DifficultyPotential for Tolerance